COMBIVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
COMBIVENT by Boehringer Ingelheim is respimat: combivent respimat is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIVENT RESPIMAT is a fixed-dose combination inhaler containing ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 agonist) for treating chronic obstructive pulmonary disease (COPD). The dual mechanism provides greater bronchodilation than either agent alone by blocking muscarinic receptors and activating beta-2 adrenergic receptors on airway smooth muscle. It is administered via metered-dose inhaler technology.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team focus likely shifting to lifecycle management and generic transition planning.
Mechanism of Action
RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a…
Worked on COMBIVENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.